<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hsu S</submitter><funding>National Center for Advancing Translational Sciences</funding><funding>Northwest Kidney Centers</funding><funding>NCATS NIH HHS</funding><funding>NIDDK NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>National Institutes of Health</funding><funding>NIDDK</funding><funding>NIGMS NIH HHS</funding><pagination>106047</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8837693</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>217</volume><pubmed_abstract>The formation of 24,25-dihydroxyvitamin D (24,25(OH)&lt;sub>2&lt;/sub>D) from 25-hydroxyvitamin D (25(OH)D) is the primary mechanism for the metabolic clearance of 25(OH)D, and is regulated by tissue-level vitamin D activity. The ratio of 24,25(OH)&lt;sub>2&lt;/sub>D&lt;sub>3&lt;/sub> to 25(OH)D&lt;sub>3&lt;/sub> in blood (vitamin D metabolite ratio, VDMR) is postulated to be a marker of 25(OH)D&lt;sub>3&lt;/sub> clearance, however this has never been tested. We measured baseline 24,25(OH)&lt;sub>2&lt;/sub>D&lt;sub>3&lt;/sub> and 25(OH)D&lt;sub>3&lt;/sub&gt; concentrations in 87 participants by liquid chromatography-tandem mass spectrometry. Following an infusion of deuterated 25(OH)D&lt;sub>3&lt;/sub>, blood samples for each participant were collected over 56 days and analyzed for deuterated vitamin D metabolites. 25(OH)D&lt;sub>3&lt;/sub> clearance and the deuterated metabolite-to-parent AUC ratio (ratio of the AUC of deuterated 24,25(OH)&lt;sub>2&lt;/sub>D&lt;sub>3&lt;/sub> to that of deuterated 25(OH)D&lt;sub>3&lt;/sub>) were calculated. We compared the VDMR with these two measures using correlation coefficients and linear regression. Participants had a mean age of 64 ± 11years, 41 % were female, 30 % were self-described Black, 28 % had non-dialysis chronic kidney disease (CKD) and 23 % had kidney failure treated with hemodialysis. The VDMR was strongly correlated with 25(OH)D&lt;sub>3&lt;/sub> clearance and the deuterated metabolite-to-parent AUC ratio (r = 0.51 and 0.76, respectively). Adjusting for 25(OH)D&lt;sub>3&lt;/sub> clearance or the deuterated metabolite-to-parent AUC ratio in addition to clinical covariates, lower VDMR was observed in participants with CKD and kidney failure than in healthy controls; in Black than White participants; and in those with lower serum albumin. Our findings validate the VDMR as a measure of 25(OH)D&lt;sub>3&lt;/sub> clearance. This relationship was biased by characteristics including race and kidney disease, which warrant consideration in studies assessing the VDMR.</pubmed_abstract><journal>The Journal of steroid biochemistry and molecular biology</journal><pubmed_title>Validation of the 24,25-dihydroxyvitamin D&lt;sub>3&lt;/sub> to 25-hydroxyvitamin D&lt;sub>3&lt;/sub> ratio as a biomarker of 25-hydroxyvitamin D&lt;sub>3&lt;/sub> clearance.</pubmed_title><pmcid>PMC8837693</pmcid><funding_grant_id>2T32DK007467</funding_grant_id><funding_grant_id>T32 HL007028</funding_grant_id><funding_grant_id>R01GM63666</funding_grant_id><funding_grant_id>F32 DK128986</funding_grant_id><funding_grant_id>R01DK099199-S1</funding_grant_id><funding_grant_id>1F32DK128986-01</funding_grant_id><funding_grant_id>P30 DK040561</funding_grant_id><funding_grant_id>R01 DK099199</funding_grant_id><funding_grant_id>T32 DK007467</funding_grant_id><funding_grant_id>P30 DK035816</funding_grant_id><funding_grant_id>R01 GM063666</funding_grant_id><funding_grant_id>UL1 TR002319</funding_grant_id><pubmed_authors>Hsu S</pubmed_authors><pubmed_authors>Lin YS</pubmed_authors><pubmed_authors>Hoofnagle AN</pubmed_authors><pubmed_authors>Best CM</pubmed_authors><pubmed_authors>de Boer IH</pubmed_authors><pubmed_authors>Thummel KE</pubmed_authors><pubmed_authors>Kestenbaum BR</pubmed_authors><pubmed_authors>Zelnick LR</pubmed_authors></additional><is_claimable>false</is_claimable><name>Validation of the 24,25-dihydroxyvitamin D&lt;sub>3&lt;/sub> to 25-hydroxyvitamin D&lt;sub>3&lt;/sub> ratio as a biomarker of 25-hydroxyvitamin D&lt;sub>3&lt;/sub> clearance.</name><description>The formation of 24,25-dihydroxyvitamin D (24,25(OH)&lt;sub>2&lt;/sub>D) from 25-hydroxyvitamin D (25(OH)D) is the primary mechanism for the metabolic clearance of 25(OH)D, and is regulated by tissue-level vitamin D activity. The ratio of 24,25(OH)&lt;sub>2&lt;/sub>D&lt;sub>3&lt;/sub> to 25(OH)D&lt;sub>3&lt;/sub> in blood (vitamin D metabolite ratio, VDMR) is postulated to be a marker of 25(OH)D&lt;sub>3&lt;/sub> clearance, however this has never been tested. We measured baseline 24,25(OH)&lt;sub>2&lt;/sub>D&lt;sub>3&lt;/sub> and 25(OH)D&lt;sub>3&lt;/sub&gt; concentrations in 87 participants by liquid chromatography-tandem mass spectrometry. Following an infusion of deuterated 25(OH)D&lt;sub>3&lt;/sub>, blood samples for each participant were collected over 56 days and analyzed for deuterated vitamin D metabolites. 25(OH)D&lt;sub>3&lt;/sub> clearance and the deuterated metabolite-to-parent AUC ratio (ratio of the AUC of deuterated 24,25(OH)&lt;sub>2&lt;/sub>D&lt;sub>3&lt;/sub> to that of deuterated 25(OH)D&lt;sub>3&lt;/sub>) were calculated. We compared the VDMR with these two measures using correlation coefficients and linear regression. Participants had a mean age of 64 ± 11years, 41 % were female, 30 % were self-described Black, 28 % had non-dialysis chronic kidney disease (CKD) and 23 % had kidney failure treated with hemodialysis. The VDMR was strongly correlated with 25(OH)D&lt;sub>3&lt;/sub> clearance and the deuterated metabolite-to-parent AUC ratio (r = 0.51 and 0.76, respectively). Adjusting for 25(OH)D&lt;sub>3&lt;/sub> clearance or the deuterated metabolite-to-parent AUC ratio in addition to clinical covariates, lower VDMR was observed in participants with CKD and kidney failure than in healthy controls; in Black than White participants; and in those with lower serum albumin. Our findings validate the VDMR as a measure of 25(OH)D&lt;sub>3&lt;/sub> clearance. This relationship was biased by characteristics including race and kidney disease, which warrant consideration in studies assessing the VDMR.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2024-11-20T08:01:45.337Z</modification><creation>2024-11-20T08:01:45.337Z</creation></dates><accession>S-EPMC8837693</accession><cross_references><pubmed>34954017</pubmed><doi>10.1016/j.jsbmb.2021.106047</doi></cross_references></HashMap>